TotalMarketCap

Kymera Therapeutics

KYMRNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$9.134 B

$109.85 +2.29%

Close of 6 Oct 2026

As of 6 Oct 2026, Kymera Therapeutics (KYMR) has a market capitalization of $9.13B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$39.2M

#2807 by revenue

Earnings

$311.4M

#820 by earnings

Shares outstanding

83,150,618

Latest filing cover page

P/E ratio

29.3

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →
  1. #16QiagenQGEN$9.44B
  2. #17RepligenRGEN$9.27B
  3. #18Kymera TherapeuticsKYMR$9.13B
  4. #19ImmunovantIMVT$6.87B
  5. #20Iovance BiotherapeuticsIOVA$6.41B

What if Kymera Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.8T

$346,731.15

Per share 3,156× higher

Bitcoin $1.68T

$20,241.63

Per share 184× higher

Nvidia $5.76T

$69,241.70

Per share 630× higher

Or at a round number

$20.0B$50.0B$100.0B$200.0B

Where these numbers come from

Share counts and financials for Kymera Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 7 Oct 2026. Read the methodology.